TY - JOUR
T1 - Acquired von Willebrand syndrome in continuous-flow ventricular assist device recipients
AU - Crow, Sheri
AU - Chen, Dong
AU - Milano, Carmelo
AU - Thomas, William
AU - Joyce, Lyle
AU - Piacentino, Valentino
AU - Sharma, Riti
AU - Wu, Jogin
AU - Arepally, Gowthami
AU - Bowles, Dawn
AU - Rogers, Joseph
AU - Villamizar-Ortiz, Nestor
PY - 2010/10
Y1 - 2010/10
N2 - Background: Bleeding is a major cause of morbidity in recipients of continuous-flow left ventricular assist devices (CF-LVAD). A better understanding of the impact of CF-LVAD support on the hemostatic profile is necessary to establish better strategies for anticoagulation therapy and risk assessment for bleeding complications. A prospective multicenter study was conducted to characterize von Willebrand factor (vWF) profiles in patients undergoing CF-LVAD implantation. Methods: Blood samples were collected before and after CF-LVAD implantation from 37 patients between July 2008 and April 2009 at Duke University and the University of Minnesota. Blood samples were analyzed for vWF, platelet and collagen-binding ability. The presence of high-molecular-weight (HMW) vWF multimers were detected through gel electrophoresis, and deficiency was graded on a scale of 0 (normal) to 3 (severe loss). Results: All 37 patients exhibited significant loss of HMW vWF multimers within 30 days of CF-LVAD implantation. Ten of the 37 patients experienced bleeding complications after CF-LVAD placement. Conclusions: All CF-LVAD recipients had acquired von Willebrand syndrome after LVAD placement, demonstrated by reduced or absent HMW vWF multimer levels. However, not all recipients had bleeding complications. These findings suggest that loss of HMW vWF multimers alone cannot predict bleeding risk. Further refinement of laboratory techniques and a larger follow-up is required to identify risk factors for bleeding in CF-LVAD recipients.
AB - Background: Bleeding is a major cause of morbidity in recipients of continuous-flow left ventricular assist devices (CF-LVAD). A better understanding of the impact of CF-LVAD support on the hemostatic profile is necessary to establish better strategies for anticoagulation therapy and risk assessment for bleeding complications. A prospective multicenter study was conducted to characterize von Willebrand factor (vWF) profiles in patients undergoing CF-LVAD implantation. Methods: Blood samples were collected before and after CF-LVAD implantation from 37 patients between July 2008 and April 2009 at Duke University and the University of Minnesota. Blood samples were analyzed for vWF, platelet and collagen-binding ability. The presence of high-molecular-weight (HMW) vWF multimers were detected through gel electrophoresis, and deficiency was graded on a scale of 0 (normal) to 3 (severe loss). Results: All 37 patients exhibited significant loss of HMW vWF multimers within 30 days of CF-LVAD implantation. Ten of the 37 patients experienced bleeding complications after CF-LVAD placement. Conclusions: All CF-LVAD recipients had acquired von Willebrand syndrome after LVAD placement, demonstrated by reduced or absent HMW vWF multimer levels. However, not all recipients had bleeding complications. These findings suggest that loss of HMW vWF multimers alone cannot predict bleeding risk. Further refinement of laboratory techniques and a larger follow-up is required to identify risk factors for bleeding in CF-LVAD recipients.
UR - http://www.scopus.com/inward/record.url?scp=77957167053&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77957167053&partnerID=8YFLogxK
U2 - 10.1016/j.athoracsur.2010.04.099
DO - 10.1016/j.athoracsur.2010.04.099
M3 - Article
C2 - 20868825
AN - SCOPUS:77957167053
SN - 0003-4975
VL - 90
SP - 1263
EP - 1269
JO - Annals of Thoracic Surgery
JF - Annals of Thoracic Surgery
IS - 4
ER -